Yulia, 432 patient favipiravir late treatment study: 85% lower mortality [p=0.05] https://c19p.org/yulia
copied to clipboard
Evaluation of Antibacterial and Antiviral Drug Effectiveness in COVID-19 Therapy: A Data-Driven Retrospective Approach
et al., Pathophysiology, doi:10.3390/pathophysiology29010009
Retrospective hospitalized patients in Indonesia, showing lower mortality and shorter hospitalization with favipiravir.
|
risk of death, 85.3% lower, OR 0.15, p = 0.05, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Yulia et al., 3/7/2022, retrospective, Indonesia, South Asia, peer-reviewed, median age 46.0, 10 authors, study period July 2020 - December 2020.
Contact:
fauna@staff.ubaya.ac.id (corresponding author), rika_y@staff.ubaya.ac.id, putriayuirma@gmail.com, rudd_apt@yahoo.com, purisafitrihanum@staff.ubaya.ac.id, herwyno@staff.ubaya.ac.id, lestionoapt@gmail.com, deramdani123@gmail.com, abusuquf@yahoo.co.id, kevin.kantono@aut.ac.nz.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.